Date: 2014-12-19
Type of information: Nomination
Compound: member of the board of directors
Company: BTG (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 19, 2014, BTG, the specialist healthcare company, announced the appointment of Dr. Susan Foden as a non-executive director of the Board, effective from 1 March 2015. Susan Foden is currently Chair of BerGenBio AS and Cizzle Biotech Ltd, holds non-executive roles with Vectura Group plc, Evgen Ltd, Source Bioscience plc and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund). Previously Susan has held the positions of Investor Director with the venture capital firm Merlin Biosciences, CEO of the technology transfer company, Cancer Research Campaign Technology Ltd and Head of Academic Liaison at Celltech Ltd. She studied Natural Sciences/Biochemistry and has an MA and DPhil from the University of Oxford.
Financial terms:
Latest news:
Is general: Yes
